Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000666798 | SCV000791154 | pathogenic | Ellis-van Creveld syndrome | 2017-05-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000695327 | SCV000823819 | pathogenic | Ellis-van Creveld syndrome; Curry-Hall syndrome | 2023-03-08 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Glu292*) in the EVC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EVC are known to be pathogenic (PMID: 23220543). This variant is present in population databases (rs527255616, gnomAD 0.004%). This premature translational stop signal has been observed in individuals with Ellis-van Creveld syndrome (PMID: 17024374, 19810119). ClinVar contains an entry for this variant (Variation ID: 551674). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000695327 | SCV002778061 | pathogenic | Ellis-van Creveld syndrome; Curry-Hall syndrome | 2022-02-17 | criteria provided, single submitter | clinical testing | |
Laboratorio de Genetica e Diagnostico Molecular, |
RCV000666798 | SCV003806825 | pathogenic | Ellis-van Creveld syndrome | 2023-02-03 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PVS1 very strong, PM2 supporting, PM3 strong |
Natera, |
RCV000666798 | SCV001454794 | pathogenic | Ellis-van Creveld syndrome | 2020-09-16 | no assertion criteria provided | clinical testing | |
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV001724122 | SCV001956371 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001724122 | SCV001974370 | pathogenic | not provided | no assertion criteria provided | clinical testing |